Neurol. praxi. 2015;16(6):347-351

Cognitive impairment in multiple sclerosis

MUDr. Zbyšek Pavelek, doc. MUDr. Martin Vališ, Ph.D.
Neurologická klinika LF a FN Hradec Králové, Hradec Králové

Multiple sclerosis is a chronic inflammatory disease which is characterized by infiltration of leukocytes into the central nervous system. This situation leads to the destruction of myelin and to the loss of axons and olidendrocytes. Cognitive dysfunction is present in all stages of multiple sclerosis. The impairment of information processing, memory and executive functions are typical findings. The NEDA-4 concept, testing of cognitive dysfunction and treatment are discussed.

Keywords: multiple sclerosis, NEDA-4, cognitive dysfunction

Published: December 16, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pavelek Z, Vališ M. Cognitive impairment in multiple sclerosis. Neurol. praxi. 2015;16(6):347-351.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bagert B, Camplair P, Bourdette D. Cognitive dysfunction in multiple sclerosis. Natural history, pathophysiology and management. CNS Drugs. 2002; 16: 445-455. Go to original source...
    2. Beier M, Bombardier CH, Hartoonian N, Motl RW, Kraft GH. Improved physical fitness correlates with improved cognition in multiple sclerosis. Arch Phys Med Rehabil. 2014; 95(7): 1328-1334. Go to original source...
    3. Benedict RH, Fischer JS, Archibald CJ, Arnett PA, Beatty WW, Bobholz J, Chelune GJ, Fisk JD, Langdon DW, Caruso L, Foley F, LaRocca NG, Vowels L, Weinstein A, DeLuca J, Rao SM, Munschauer F. Minimal neuropsychological assessment of MS patients: a consensus approach. Clin Neuropsychol. 2002; 16(3): 381-397. Go to original source...
    4. Bobholz JA, Rao SM. Cognitive dysfunction in multiple sclerosis: a review of recent developments. Curr Opin Neurol. 2003; 16(3): 283-288. Go to original source... Go to PubMed...
    5. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L; TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010; 362(5): 402-415. Go to original source...
    6. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA; CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012; 380(9856): 1819-1828. Go to original source...
    7. Fischer JS, Priore RL, Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Goodkin DE, Granger CV, Simon JH, Grafman JH, Lezak MD, O'Reilly Hovey KM, Perkins KK, Barilla-Clark D, Schacter M, Shucard DW, Davidson AL, Wende KE, Bourdette DN, Kooijmans-Coutinho MF. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol. 2000; 48(6): 885-892. Go to original source...
    8. Giovannoni G, Gold R, Kappos L, Arnold DL, Bar-Or A, Kurukulasuriya NC, Yang M, Sarda SP. Delayed-Release Dimethyl Fumarate and Disability Assessed by the Multiple Sclerosis Functional Composite: Integrated Analysis of DEFINE and CONFIRM. Boston, MA, USA, 10-13, September 2014; P057.
    9. Ghezzi A, Goretti B, Portaccio E, Roscio M, Amato MP. Cognitive impairment in pediatric multiple sclerosis. Neurol Sci. 2010; 31(Suppl 2): S215-218. Go to original source... Go to PubMed...
    10. Gold R, Hartung H, Stangel M, Wiendl H, Zipp F, Expertenmeetings T. Therapeutic goals of baseline and escalation therapy for relapsing-remitting multiple sclerosis. Akt Neurol. 2012; 39: 342-350. Go to original source...
    11. Goverover Y, Genova HM, Hillary FG, DeLuca J. The relationship between neuropsychological measures and the Timed Instrumental Activities of Daily Living task in multiple sclerosis. Mult Scler. 2007; 13(5): 636-644. Go to original source... Go to PubMed...
    12. Grassiot B, Desgranges B, Eustace F, Defer G. Quantification and clinical relevance of brain atrophy in multiple sclerosis: a review. J Neurol 2009; 256: 1397-1412. Go to original source... Go to PubMed...
    13. Hartl P, Hartlová H. Psychologický slovník. Praha: Portál, 2000: 776.
    14. Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, O'Connor PW, Giovannoni G, Phillips JT, Lublin FD, Pace A, Kim R, Hyde R. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009; 8(3): 254-260. Go to original source... Go to PubMed...
    15. Hirst C, Ingram G, Pearson O, Pickersgill T, Scolding N, Robertson N. Contribution of relapses to disability in multiple sclerosis. J Neurol. 2008; 255: 280-287. Go to original source... Go to PubMed...
    16. Chiaravalloti ND., DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol. 2008; 7(12): 1139-1151. Go to original source...
    17. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalbán X, Barkhof F, Radü EW, Metzig C, Bauer L, Lanius V, Sandbrink R, Pohl C; BENEFIT Study Group. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol. 2009; 8(11): 987-997. Go to original source...
    18. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010; 362(5): 387-401. Go to original source...
    19. Khalil M, Enzinger C, Langkammer C, Petrovic K, Loitfelder M, Tscherner M, Jehna M, Bachmaier G, Wallner-Blazek M, Ropele S, Schmidt R, Fuchs S, Fazekas F. Cognitive impairment in relation to MRI metrics in patients with clinically isolated syndrome. Mult Scler. 2011; 17(2): 173-180. Go to original source... Go to PubMed...
    20. Krejsek J. Novinky v patogenezi roztroušené sklerózy. Co je skryto za disabilitou pacientů s RS. Remedia, 2014: S2-4.
    21. Krupp LB, Christodoulou C, Melville P, Scherl WF, Pai LY, Muenz LR, He D, Benedict RH, Goodman A, Rizvi S, Schwid SR, Weinstock-Guttman B, Westervelt HJ, Wishart H. Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. Neurology. 2011; 76(17): 1500-1507. Go to original source...
    22. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33(11): 1444-1452. Go to original source... Go to PubMed...
    23. Langdon DW, Thompson AJ. Multiple sclerosis: a preliminary study of selected variables affecting rehabilitation outcome. Mult Scler. 1999; 5(2): 94-100. Go to original source... Go to PubMed...
    24. Leray E, Yaouanq J, Le Page E, Coustans M, Laplaud D, Oger J, Edan G. Evidence for a two-stage disability progression in multiple sclerosis. Brain. 2010; 133: 1900-1913. Go to original source...
    25. LoPresti P. Glatiramer acetate guards against rapid memory decline during relapsing-remitting experimental autoimmune encephalomyelitis. Neurochem Res. 2015; 40(3): 473-479. Go to original source... Go to PubMed...
    26. Lovera JF, Frohman E, Brown T, Bandari D, Whitman R, Wild K, Bourdette D. randomized double-blindplacebo controlled trial of memantine 10mg twice a day for three months as a treatment for cognitive impairment in multiple sclerosis. Neurology 72, 2009; March 17(Suppl4) : 112-113.
    27. Miller A, O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Truffinet P, Wang L, Freedman MS, for the Teriflunomide Multiple Sclerosis Trial Group, Amsterdam, the Netherlands, 19-22, October, 2011; P438.
    28. Morrow SA, Weinstock-Guttman B, Munschauer FE, Hojnacki D, Benedict RH. Subjective fatigue is not associated with cognitive impairment in multiple sclerosis: cross-sectional and longitudinal analysis. Mult Scler. 2009; 15(8): 998-1005. Go to original source... Go to PubMed...
    29. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdová E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O?Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302. Go to original source...
    30. Potagas C, Giogkaraki E, Koutsis G, Mandellos D, Tsirempolou E, Sfagos C, Vassilopoulos D. Cognitive impairment in different MS subtypes and clinically isolated syndromes. J Neurol Sci. 2008; 267(1-2): 100-106. Go to original source...
    31. Preiss M., Křivohlavý J. Trénování paměti a poznávacích schopností. Praha: Grada Publishing, a.s., 2009: 208. ISBN 978-80-247-2738-7.
    32. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology. 1991; 41(5): 685-691. Go to original source... Go to PubMed...
    33. Reuter F, Zaaraoui W, Crespy L, Faivre A, Rico A, Malikova I, Confort-Gouny S, Cozzone PJ, Ranjeva JP, Pelletier J, Audoin B. Cognitive impairment at the onset of multiple sclerosis: relationship to lesion location. Mult Scler. 2011; 17(6): 755-758. Go to original source... Go to PubMed...
    34. Río J, Rovira A, Tintoré M, Huerga E, Nos C, Tellez N, Tur C, Comabella M, Montalban X. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients. Mult Scler. 2008; 14(4): 479-484. Go to original source... Go to PubMed...
    35. Scalfari A, Neuhaus A, Degenhardt A, Rice G, Muraro P, Daumer M, Ebers GC. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain. 2010; 133: 1914-1929. Go to original source... Go to PubMed...
    36. Schwartz CE, Snook E, Quaranto B, Benedict RH, Vollmer T. Cognitive reserve and patient-reported outcomes in multiple sclerosis. Mult Scler. 2013; 19(1): 87-105. Go to original source... Go to PubMed...
    37. Sumowski JF, Chiaravalloti N, Wylie G, Deluca J. Cognitive reserve moderates the negative effect of brain atrophy on cognitive efficiency in multiple sclerosis. J Int Neuropsychol Soc. 2009; 15(4): 606-612. Go to original source... Go to PubMed...
    38. Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y. Impact of multiple sclerosis relapses on progression diminishes with time. Neurology. 2009; 73: 1616-1623. Go to original source... Go to PubMed...
    39. Villoslada P, Arrondo G, Sepulcre J, Artieda J. Memantine induces reversible neurologic impairment in patients withs MS. Neurology 2008 Dec 17 (Epub). Go to original source...
    40. Vogt A, Kappos L, Calabrese P, Stöcklin M, Gschwind L, Opwis K, Penner IK. Working memory training in patients with multiple sclerosis - comparison of two different training schedules. Restor Neurol Neurosci. 2009; 27(3): 225-235. Go to original source...
    41. Weinshenker B, Bass B, Rice G, Noseworthy J, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain. 1989; 112(Pt 6): 1419-1428. Go to original source... Go to PubMed...
    42. Weinstein A, Schwid SR, Schiffer RB, McDermott MP, Giang DW, Goodman AD. Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol. 1999; 56(3): 319-324. Go to original source...
    43. Weinstock-Guttman B, Galetta SL, Giovannoni G, Havrdova E, Hutchinson M, Kappos L, O'Connor PW, Phillips JT, Polman C, Stuart WH, Lynn F, Hotermans C. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. J Neurol. 2012; 259(5): 898-905. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.